A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
The new model of care will seek to increase value-based care for patients receiving chemotherapy.
New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.
Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.
Sometimes nurses inappropriately handle high-risk medications. It is important that other nurses, especially those who work in pain management, hold colleagues accountable to promote patient safety.
Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.
Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.
Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.
Researchers with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and the University’s Frost School of Music are using a $2.6 million federal grant to study how mindfulness and music therapy can alleviate stress, anxiety, and depression, reduce treatment-related symptoms, and improve quality of life for cancer patients and survivors.
The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.
Nurse investigators created an enteral nutrition standardized pathway for pediatric patients about undergoing hematopoietic stem cell transplantation.
Trastuzumab and pertuzumab with a chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel increased response, and high-grade toxicity, in patients with HER2-positive gastric or gastroesophageal junction cancer.
For this episode of “The Vitals,” Aliènne Salleroli, MS, BSN, RN, OCN, discusses her research on equity, diversity, and inclusion in oncology nurse leadership.
Private Medicare beneficiaries face high access barriers and increased mortality rates following oncologic resection than patients with traditional Medicare plans.
In November 2022, HER2-directed therapies made headlines in breast cancer as did innovations to help individuals who are often overlooked in oncology care.
Pembrolizumab plus physician’s choice of chemotherapy bested placebo plus chemotherapy in improving overall survival rates in patients with HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.
In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.
Disease-free survival in patients with metastatic breast cancer did not differ between treatment with everolimus or placebo.
Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Combining the doxorubicin analogue camsirubicin with pegfilgrastim yielded encouraging clinical activity in patients with advanced soft tissue sarcoma.
Margetuximab did not deliver a significant survival benefit in patients with HER2-positive advanced breast cancer compared with trastuzumab.
Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.
The autologous tumor lysate-loaded dendritic cell vaccination reduced the risk of death for patients with newly diagnosed glioblastoma by 20%.
Providing oncologists with a baseline geriatric assessment summary with guidelines to manage toxicities may help reduce symptom burden in older patients with advanced cancer.
Ibrutinib demonstrated encouraging responses for patients with relapsed/refractory mantle cell lymphoma in a real-world setting.
The combination of tremelimumab plus durvalumab plus chemotherapy, which was recently approved for patients with non–small cell lung cancer, could represent a new standard of care.
